JAK inhibition for CD3− CD4+ lymphocytic-variant ...
Type de document :
Compte-rendu et recension critique d'ouvrage: Autre communication scientifique (congrès sans actes - poster - séminaire...)
Titre :
JAK inhibition for CD3− CD4+ lymphocytic-variant hypereosinophilic syndrome
Auteur(s) :
Faguer, Stanislas [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Institut des Maladies Métaboliques et Casdiovasculaires [UPS/Inserm U1297 - I2MC]
Groh, Matthieu [Auteur]
Hôpital Foch [Suresnes]
Vergez, François [Auteur]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Hunault-Berger, Mathilde [Auteur]
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers [CRCI2NA ]
Duployez, Nicolas [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Renaudineau, Yves [Auteur]
Institut Fédératif de Biologie (IFB)
Institut Toulousain des Maladies Infectieuses et Inflammatoires [Infinity]
Université Toulouse III - Paul Sabatier [UT3]
Paul, Carle [Auteur]
Unité différenciation épidermique et auto-immunité rhumatoïde [UDEAR]
Lefevre, Guillaume [Auteur]
Institute of Chemistry for Life and Health Sciences [iCLeHS]
Kahn, Jean-Emmanuel [Auteur]
Hôpital Ambroise Paré [AP-HP]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Institut des Maladies Métaboliques et Casdiovasculaires [UPS/Inserm U1297 - I2MC]
Groh, Matthieu [Auteur]
Hôpital Foch [Suresnes]
Vergez, François [Auteur]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Hunault-Berger, Mathilde [Auteur]
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers [CRCI2NA ]
Duployez, Nicolas [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Renaudineau, Yves [Auteur]
Institut Fédératif de Biologie (IFB)
Institut Toulousain des Maladies Infectieuses et Inflammatoires [Infinity]
Université Toulouse III - Paul Sabatier [UT3]
Paul, Carle [Auteur]
Unité différenciation épidermique et auto-immunité rhumatoïde [UDEAR]
Lefevre, Guillaume [Auteur]
Institute of Chemistry for Life and Health Sciences [iCLeHS]
Kahn, Jean-Emmanuel [Auteur]
Hôpital Ambroise Paré [AP-HP]
Titre de la revue :
Clinical Immunology
Pagination :
109275
Éditeur :
Elsevier
Date de publication :
2023-03
ISSN :
1521-6616
Mot(s)-clé(s) en anglais :
Hypereosinophilic syndrome
JAK inhibition
Lymphocytic variant
Ruxolitinib
T-cell clone. Copyright © 2023. Published by Elsevier Inc.
JAK inhibition
Lymphocytic variant
Ruxolitinib
T-cell clone. Copyright © 2023. Published by Elsevier Inc.
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Alternatives are urgently needed in patients with CD3- CD4+ lymphocytic-variant hypereosinophilic syndrome (L-HES) requiring high-level steroids or who are unresponsive and/or intolerant to conventional alternative therapies. ...
Lire la suite >Alternatives are urgently needed in patients with CD3- CD4+ lymphocytic-variant hypereosinophilic syndrome (L-HES) requiring high-level steroids or who are unresponsive and/or intolerant to conventional alternative therapies. We report five L-HES patients (44-66 years) with cutaneous involvement (n = 5) and persistent eosinophilia (n = 3) despite conventional therapies, who successfully received JAK inhibitors (tofacitinib n = 1, ruxolitinib n = 4). JAKi led to complete clinical remission in the first 3 months in all (with prednisone withdrawal in four). Absolute eosinophil counts normalized in cases receiving ruxolitinib, while reduction was partial under tofacitinib. After switch from tofacitinib to ruxolitinib, complete clinical response persisted despite prednisone withdrawal. The clone size remained stable in all patients. After 3-13 months of follow-up, no adverse event was reported. Randomized controlled trials are now mandatory to optimize the use of JAKi in L-HES.Lire moins >
Lire la suite >Alternatives are urgently needed in patients with CD3- CD4+ lymphocytic-variant hypereosinophilic syndrome (L-HES) requiring high-level steroids or who are unresponsive and/or intolerant to conventional alternative therapies. We report five L-HES patients (44-66 years) with cutaneous involvement (n = 5) and persistent eosinophilia (n = 3) despite conventional therapies, who successfully received JAK inhibitors (tofacitinib n = 1, ruxolitinib n = 4). JAKi led to complete clinical remission in the first 3 months in all (with prednisone withdrawal in four). Absolute eosinophil counts normalized in cases receiving ruxolitinib, while reduction was partial under tofacitinib. After switch from tofacitinib to ruxolitinib, complete clinical response persisted despite prednisone withdrawal. The clone size remained stable in all patients. After 3-13 months of follow-up, no adverse event was reported. Randomized controlled trials are now mandatory to optimize the use of JAKi in L-HES.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Collections :
Source :